COMPANY ANNOUNCEMENTKarmelSonix Sales Commence in South Korea19...

COMPANY ANNOUNCEMENT
KarmelSonix Sales Commence in South Korea
19 May 2011 : KarmelSonix Ltd ( KSX) today announced that orders valued at $45,000 USD
have been taken for their PulmoTrack? and WHolterTM devices for placement into respiratory
units across Korea, including one of Korea?s leading respiratory Hospitals.
The Korean University Medical Centre (KUMC) is a 1000-bed large medical facility, fully
devoted to elevating its medical service quality by introducing state-of-the-art equipment and
systems. KUMC works in close collaboration with leading departments in prominent
universities across the world, including MD Anderson Center in the USA and Hokkaido
University Hospital in Japan.
Asthma morbidity and mortality in Korea are steadily increasing. The prevalence of asthma in
Korea is estimated to be 3.9% (that being nearly 2 million people) and its severity is often
underestimated by both physicians and patients. Mortality resulting from chronic lower
respiratory diseases including asthma increased from 12.9 to 22.6 deaths per 100,000 of the
population between 1992 and 2002. (1) The prevalence of Chronic Obstructive Pulmonary
Disease (COPD) was substantially higher at around 13% (that being 6.3 million people).
The PulmoTrack? will be used for continuous monitoring of wheeze and cough in the hospital
environment, whereas the WHolterTM will be used in the home environment. Patients with
suspected nocturnal wheeze or cough will be sent home with a WHolterTM, and upon the
patients return to the physician, they will receive an accurate analysis of whether or not they
were wheezing or coughing overnight, and importantly the quantification of how often and
how many episodes occurred. Once this is known, the patient can immediately be placed on a
recommended treatment protocol to manage their asthma or COPD.
Mr Paul Eisen, Managing Director KarmelSonix Asia Pacific noted: ?With deaths from Asthma
(and COPD) on the increase in Korea, our technology now gives the physician a complete
clinical picture. Until now, physicians in Korea were not able to determine whether a patient
coughed or wheezed at night. In fact, in many cases the patient also did not know. With
nearly 2 million patients suffering from asthma and 6 million from COPD in South Korea, this
represents a major ongoing strategic focus for us in the Asia Pacific region?.
For additional information contact:
Paul Eisen ? Managing Director Asia Pacific
+61(0) 417069887
[email protected]
?Wheeze Rate ? A New Paradigm in Asthma Management?
?Wheeze Rate ? A New Paradigm in Asthma Management?
KarmelSonix Ltd. (KSX) KarmelSonix (Israel) Ltd. KarmelSonix USA.
Suite 2, 1233 High Street
Armadale VIC 3143
Australia
Suite 2.03, 25 Solent Circuit
Norwest Business Park,
Baulkham Hills NSW 2153
Australia
16 Palyam Avenue
Haifa, 33095
Israel
8599 Haven Avenue
Alta Loma, CA 91701
USA
About KarmelSonix : KarmelSonix Ltd focuses on supplying innovative non-invasive
acoustic tools for disease management of asthma and related pulmonary disorders. Asthma
affects 6-16% of the population in developed countries with a cost exceeding $US15 billion in
the US alone.
Acoustic Asthma Management is a breakthrough in monitoring of the asthmatic patient of all
ages, including the very young, very old and others who cannot perform currently available
tests. The technology that comes from extensive R&D and clinical validation in the US, Israel
and Australia, facilitate continuous monitoring of patients at home, in the ICU and even during
sleep. The company is now focussing its efforts on early commercialization of its products
particularly in the AsiaPac, European and North American markets.
(1) J Korean Med Sci. 2006 April; 21(2): 181?187
DISCLAIMER
This update may contain certain forward-looking statements that have been based on current
expectations about future acts, events and circumstances. These forward-looking statements
are, however, subject to risks, uncertainties and assumptions that could cause those acts,
events and circumstances to differ materially from the expectations described in such forwardlooking
statements.
These factors include, among other things, commercial and other risks associated with the
achieving of adequate commercial sales of the Company?s products, the meeting of objectives
and other investment considerations, as well as other matters not yet known to the Company
or not currently considered material by the Company.
KarmelSonix accepts no responsibility to update any person regarding any error or omission or
change in the information in this update or any other information made available to a person or
any obligation to furnish the person with further information, other than in accordance with ASX
or other applicable laws or regulations.